| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Darolutamide (JAN/USAN/INN); Nebeqa (TN) | ||||||
| Product | NUBEQA (Bayer HealthCare Pharmaceuticals) | ||||||
| Formula | C19H19ClN6O2 | ||||||
| Exact mass | 398.1258 | ||||||
| Mol weight | 398.8462 | ||||||
| Structure |  | ||||||
| Class | Antineoplastic DG01591 Androgen receptor antagonist DG01624 Flutamide-type antiandrogen | ||||||
| Remark |
| ||||||
| Efficacy | Antineoplastic, Androgen receptor antagonist | ||||||
| Disease | Prostate cancer [DS:H00024] | ||||||
| Target | NR3C4 (AR) [HSA:367] [KO:K08557] | ||||||
| Pathway |
| ||||||
| Interaction | |||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L02 ENDOCRINE THERAPY L02B HORMONE ANTAGONISTS AND RELATED AGENTS L02BB Anti-androgens L02BB06 Darolutamide D11045 Darolutamide (JAN/USAN/INN) <JP/US> USP drug classification [BR:br08302] Antineoplastics Antiandrogens Darolutamide D11045 Darolutamide (JAN/USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 42 Antineoplastics 429 Miscellaneous 4291 Other Antitumors D11045 Darolutamide (JAN/USAN/INN) Drug groups [BR:br08330] Antineoplastic DG01591 Androgen receptor antagonist DG01624 Flutamide-type antiandrogen D11045 Darolutamide Drug classes [BR:br08332] Antineoplastic DG01591 Androgen receptor antagonist D11045 Darolutamide Target-based classification of drugs [BR:br08310] Nuclear receptors Estrogen like receptors 3-Ketosteroid receptor NR3C4 (AR) D11045 Darolutamide (JAN/USAN/INN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D11045 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D11045 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D11045 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D11045 | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 28 1 C8x C 21.1400 -14.7000 2 C8y C 21.1400 -13.3000 3 C8y C 19.9500 -12.6000 4 C8x C 18.6900 -13.3000 5 C8y C 18.6900 -14.7000 6 C8x C 19.9500 -15.4000 7 X Cl 19.9500 -11.2000 8 C3b C 22.3300 -12.6000 9 N3a N 23.5900 -11.9000 10 C8y C 17.5000 -15.4000 11 N4y N 15.2600 -15.4000 12 C8x C 15.6800 -16.7300 13 C8x C 17.0800 -16.7300 14 N5x N 16.3800 -14.5600 15 C1b C 14.0700 -14.7000 16 C1c C 12.8800 -15.4000 17 N1b N 11.6900 -14.7000 18 C5a C 10.5000 -15.4000 19 C8y C 9.3100 -14.7000 20 C8x C 8.8900 -13.3700 21 C8y C 7.4900 -13.3700 22 N4x N 7.0700 -14.7000 23 N5x N 8.1900 -15.5400 24 C1c C 6.3000 -12.6700 25 C1a C 5.1100 -13.3700 26 O1a O 6.3000 -11.2700 27 O5a O 10.5000 -16.8000 28 C1a C 12.8800 -16.8000 BOND 30 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 3 7 1 8 2 8 1 9 8 9 3 10 5 10 1 11 11 12 1 12 12 13 2 13 13 10 1 14 11 14 1 15 14 10 2 16 11 15 1 17 15 16 1 18 16 17 1 19 17 18 1 20 18 19 1 21 19 20 1 22 20 21 2 23 21 22 1 24 22 23 1 25 23 19 2 26 21 24 1 27 24 25 1 28 24 26 1 29 18 27 2 30 16 28 1 #Down |